Cerba Research
Cerba Research is recorded as a service provider in 99 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 99 trials · Latest update first
A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
Sponsor Johnson & Johnson Enterprise Innovation Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Following FDA IND review, the protocol broadened exclusions for factors associated with QTc prolongation and torsades de pointes risk, revised the dose-limiting-toxicity definition, and reduced the Part 1 target toxicity rate from 30% to 20%.
- The protocol reduced Part 2 cohort expansion from 100 to 20 participants per dosing schedule, added 6/28- and 20/28-day dosing schedules for Part 2, and reduced the overall planned study population.
- Part 2 enrollment suspension rules based on prespecified safety and efficacy criteria were added.
- A 2022 amendment aligned post-treatment contraception, pregnancy-testing, pregnancy-counselling, and gamete-donation guidance with CTFG recommendations; the sponsor stated these changes were not driven by new safety data or health-authority feedback.
These findings describe the trial, not the service provider’s performance or responsibility.
A phase 3 randomized, observer-blind, controlled study to evaluate the clinical efficacy of an mRNA- based seasonal influenza vaccine in older adults ≥65 years of age
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
Sponsor Inventiva
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population with suspected or confirmed Gram negative infections, including but not restricted to Complicated Urinary Tract Infections.
Sponsor Menarini Ricerche S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sponsor Cellectis
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Sponsor Cellectis
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid
Sponsor Ipsen Pharma
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP 101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
Sponsor Heidelberg Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, randomised, phase III study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy (SOLSTICE study).
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)
Sponsor Sanofi Vaccines US Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease
Sponsor H. Lundbeck A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 versus Investigator's Choice in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor Dizal Pharmaceutical Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents
Sponsor Fractyl Health Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Cerba Research?
The 2026-10-09 snapshot links Cerba Research to 99 distinct CTIS trials. Recorded services include Laboratory services, Clinical chemistry, Clinical haematology, Serology/ endocrinology, Assess changes in substrate degradation levels in peripheral blood immune cells and association with mezigdomide dose and exposure., Bioanalytical Lab, among 32 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Cerba Research?
The most frequently recorded therapeutic areas are Haematological Malignancies, Gastroenterology, Infectious Disease, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Cerba Research conducted?
The linked trials record locations in 27 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Cerba Research delivered services.
What can this page tell me about Cerba Research's trial experience?
Browse 99 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under Cerba Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Cerba Research
- Cerba Research Europe B.V.
- Cerba Research USA Inc.